Tolfenamic acid versus propranolol in the prophylactic treatment of migraine.
The prophylactic effect of tolfenamic acid and propranolol was studied in a randomized double-blind cross-over trial of 76 patients with migraine with or without aura. After a 4-week run-in period patients were randomly allocated to treatment with either tolfenamic acid 100 mg three times daily or propranolol 40 mg three times daily for 12 weeks. After a placebo wash-out period of 4 weeks the patients got the alternative drug for 12 weeks; 56 patients completed the study. Both drugs significantly reduced migraine attacks as judged from the reduction in the efficacy parameters (migraine hours, migraine days, and migraine intensity) in the treatment periods compared with the run-in period. No statistical significant difference in any efficacy parameter was found between the two drugs (level 2 alpha = 0.05, alpha = 0.10). The adverse effects showed no statistical difference in frequency between the 2 treatments. Twenty patients discontinued the study: 12 patients on propranolol and 8 patients on tolfenamic acid. Side effects were the cause of premature discontinuation of study medicine in 9 patients during propranolol treatment (dizziness, fatigue, and fall in blood pressure) and in 5 patients during tolfenamic acid treatment (gastrointestinal symptoms).
Department of Neurology, Soenderborg Sygehus, Copenhagen, Denmark.
M J
MJ
Kjaersgård Rasmussen
B
B
Holt Larsen
L
L
Borg
P
P
Soelberg Sørensen
P E
PE
Hansen
D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D062367:ortho-Aminobenzoates / Q000009:adverse effects / Q000627:therapeutic use*
D062367:ortho-Aminobenzoates; C009500:tolfenamic acid; D011433:Propranolol